CVRx, Inc. (CVRX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
CVRx Inc: Overreaction Creates Buying Opportunity
CVRx Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness.
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CVRx, Inc. (CVRX) Q4 2024 Earnings Conference Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ET Company Participants Mike Vallie - Investor Relations, ICR Healthcare Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Rohin Patel - JPMorgan Macauley Kilbane - William Blair William Plovanic - Canaccord Genuity Samantha Munoz - Piper Sandler Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Operator Greetings, and welcome to the CVRx Fourth Quarter 2024 Earnings Call. At this time, all participants are in a listen-only mode.
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to loss of $0.44 per share a year ago.
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?
CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CVRx: Impressive Top-Line Growth Seems Priced In
CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution.
CVRx, Inc. (CVRX) Q3 2024 Earnings Call Transcript
CVRx, Inc. (NASDAQ:CVRX ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Mike Vallie - Investor Relations Kevin Hykes - President & Chief Executive Officer Jared Oasheim - Chief Financial Officer Conference Call Participants Macauley Kilbane - William Blair Rohin Patel - JPMorgan Frank Takkinen - Lake Street Capital Market Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald. Operator Welcome to CVRx Q3 2024 Earnings Call.
CVRx (CVRX) Reports Q3 Loss, Tops Revenue Estimates
CVRx (CVRX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.43 per share a year ago.
CVRx (CVRX) Soars 17.2%: Is Further Upside Left in the Stock?
CVRx (CVRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CVRX Stock Gains on Unveiling of Barostim's Positive Study Data
CVRx announces the publication of positive study data for its Barostim therapy.
CVRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into BRONSTEIN, GEWIRTZ & GROSSMAN, LLC and Encourages Clients to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 21, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of CVRx, Inc. ("CVRx" or "the Company") (NASDAQ:CVRX). Investors who purchased CVRx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CVRX.
